Second, the murine data suggest that CCL7-blockade may be a useful therapeutic strategy to reduce inflammatory cell infiltration into the kidneys, thereby ameliorating AKI, without affecting systemic mobilization of myeloid cells that may be helpful for defense against infections. This evidence concerns the gene CCL7 and acute kidney injury.